1-3 of 3
Masafumi Miyoshi
Close
Sort by
Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3260.
https://doi.org/10.1182/blood-2018-99-116225
Published: 2018
Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo
Journal: Blood
Blood (2017) 130 (Supplement 1): 434.
https://doi.org/10.1182/blood.V130.Suppl_1.434.434
Published: 2017
Journal Articles

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Kazuteru Ohashi, Kenshi Suzuki, MD PhD, Kazutaka Sunami, MD PhD, Shinsuke Iida, MD PhD, Shinichiro Okamoto, MD PhD, Hiroshi Handa, MD PhD, Kosei Matsue, MD PhD, Masafumi Miyoshi, Eric Bleickardt, MD, Morio Matsumoto, MD, Masafumi Taniwaki, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3315.
https://doi.org/10.1182/blood.V128.22.3315.3315
Published: 2016